Compare iShares Broad USD Investment Grade Corporate Bond (USIG) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Broad USD Investment Grade Corporate Bond vs Zoetis Inc — how do they compare? iShares Broad USD Investment Grade Corporate Bond trades at $50.25, while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while iShares Broad USD Investment Grade Corporate Bond pays none. Which is the better fit depends on your goals.
| USIG | ZTS | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $52.69 | $156.76 |
52-Week Low | $50.18 | $71.91 |
Market Cap | — | $31.14B |
Enterprise Value | — | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USIG trades at $50.25, up 0.14% on the day, with a bearish technical signal driven by moving averages and neutral oscillators. Recent news includes a transaction with Tiptree Inc. and increased institutional interest from Bank of New York Mellon Corp. The stock shows consistent dividend payments, with three recent distributions totaling $0.62 per share through mid-2026.
The outlook remains cautious due to weak technical momentum and limited fundamental data visibility. Risks include reliance on corporate bond market stability and competitive pressures in the insurance sector. Analyst sentiment is neutral, with institutional accumulation suggesting long-term confidence amid near-term headwinds.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
